Pharvaris NV at Cantor Fitzgerald Global Healthcare Conference Transcript
Global Healthcare Conference, I'm Pete Stavropoulos, a biotech analyst with Cantor. With us, we have Pharvaris, and I'm now pleased to introduce the CBO, Morgan Conn. Well, welcome.
Thank you. Thanks for having us.
So let's start off with an introduction of the company for those who are less familiar.
Sure, thank you. So Pharvaris was started, gosh, or initiated about eight years ago now, with the idea of taking a proven mechanism in hereditary angioedema, which is the bradykinin inhibition of the bradykinin 2 receptor, and it would just been exemplified by a [cat event], which was invented by some of the members of our team. And turning that, using that mechanism, and exploiting that with a small molecule that could be oral to allow a formulation as both an on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
